Indian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...

India and the United States have made significant headway in their Bilateral Trade Agreement negotiations, with both nations expressing str...

India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...

Wright PMS's Sonam Srivastava champions a data-driven approach to active investing, analyzing over 300 data points to identify alpha. Her f...

Reliance Industries is poised for a turnaround, with strong earnings, a Jio Platforms IPO, and AI/energy investments promising significant ...

Indian equities are poised for fresh highs, driven by strong earnings and sector-specific momentum, particularly in financials and manufact...

Currently, India’s FTA utilisation rate hovers around 25% compared to 70-80% in developed economies.

The government will decide on extending import duty exemptions for 40 products after June 30. This decision hinges on the evolving situatio...

India and the UK's Comprehensive Economic and Trade Agreement (CETA) will take effect on July 15, granting 99% of Indian exports tariff-fre...

Indian equities face headwinds from inflation and monsoon uncertainty, yet opportunities exist. Pramod Amthe of InCred Capital highlights s...

India's long-term growth outlook remains robust despite global geopolitical uncertainties and intermittent market volatility, supported by ...

Indian stocks are poised for a favorable period. Falling crude oil prices and a strengthening rupee offer support. Macroeconomic conditions...

Indian equities offer rare discounts for investors. Nippon India Mutual Fund's Equity CIO, Sailesh Raj Bhan, advises accumulating world-cla...

Geopolitical shifts and the drive for self-reliance are creating long-term investment opportunities in India's defence and electrification ...

Easing West Asia tensions boost global markets, prompting investors to reassess opportunities. Market veteran Sudip Bandyopadhyay favors ph...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

Uzbekistan is inviting Indian drug companies to invest more. They are offering better subsidies and technology help. This aims to make Uzbe...